| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fcb093a174d5182b5854b704cb09354 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
| filingDate |
2003-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09904f9339cb19aa60fb24e3fe3bea37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c1254379c645e22478bc5cf1c31779e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f629e78ae2ce478ca19f90fb9bc6fba4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1503066aea7db9c5f9c9ea1e5614775a |
| publicationDate |
2009-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7588764-B2 |
| titleOfInvention |
Compositions comprising human immunodeficiency virus Tat adsorbed to the surface of anionic nanoparticles |
| abstract |
Non-denatured, recombinant human immunodeficiency virus (HIV) Tat that is free of bacterial RNA and endotoxin is employed in an anti-HIV vaccine. A process of producing the recombinant Tat protein includes steps for removing bacterial RNA from the recombinant Tat and for removing endotoxin from the recombinant Tat protein. A Tat-adsorbed nanoparticle formulation and method of making the same. A method of vaccinating against and/or treating HIV infection comprises administering to a subject in need of such vaccination or treatment an immune-response inducing effective amount of the recombinant Tat protein. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008124350-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013131008-A1 |
| priorityDate |
2002-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |